A targeted growth hormone blend combining Tesamorelin and Ipamorelin for enhanced visceral fat reduction and body composition improvement. Tesamorelin specifically targets visceral adipose tissue reduction through selective GHRH receptor activation, while Ipamorelin provides selective growth hormone release without affecting cortisol or prolactin.